. Author manuscript; available in PMC: 2009 Jun 23.

Published in final edited form as: Neuropsychopharmacology. 2009 Jan 14;34(7):1695–1709. doi: 10.1038/npp.2008.227

Table 3.

Effect of 5-HTT genotype on global brain cPLA₂ and COX activities and eicosanoid concentrations

	5-HTT^+/+	5-HTT^+/−	5-HTT^−/−
cPLA₂ activity (nmol/min/g protein)
	(n = 6)	(n = 7)	(n = 5)
	896.3 ± 83.7	1155 ± 95^***	1207 ± 83^***
COX activity (pg PGE₂/min/mg protein)
	(n = 6)	(n = 7)	(n = 5)
	112.4 ± 13.9	57.1 ± 9.6^***	29.0 ± 3.6^***^B
Eicosanoid concentration
	(n = 4)	(n = 4)	(n = 4)
PGE₂ (ng/g brain)	23.6 ± 1.8	6.12 ± 1.18^***	2.44 ± 0.75^*** ^A
PGF_2α (pg/g brain)	63.5 ± 4.3	48.5 ± 3.6^***	41.3 ± 3.1^***
TXB₂ (pg/g brain)	102.4 ± 24.3	67.4 ± 4.3^***	28.4 ± 2.4^*** ^A

Values are means ± SD. Bonferroni's multiple comparison tests were performed:

^***

p < 0.001

5-HTT^−/− and 5-HTT^+/− versus 5-HTT^+/+

p < 0.01

p < 0.001 5-HTT^−/− versus 5-HTT^+/−